Moreover, CDK9 inhibition by Dinaciclib resulted in markedly decreased colorectal cancer cell viability and profoundly enhanced TRAIL-mediated apoptosis of resistant colorectal cancer cells via suppression of short-living anti-apoptotic proteins Mcl-1 and c-FLIP. Here, MCL1 is linked to colorectal cancer.